gastroesophageal reflux disease

Nizatidine (Acinon) 是一种竞争性和可逆的组胺 H2 受体拮抗剂，具有抗酸活性，可用于胃溃疡的研究。

Abeprazan hydrochloride (Fexuprazan hydrochloride) 是一种有效的、可逆的、具有口服活性的potassium-competitive acid 阻滞剂，通过竞争性的与钾离子结合抑制 H+，K+- ATPase，而无需酸激活。Abeprazan hydrochloride 是一种质子泵抑制剂(PPI)，通过减少胃酸的产生而起作用，可用于治疗胃酸相关疾病，如胃食管反流病(GERD)和消化性溃疡。

PF 03716556 (PF-3716556) 是一种有效且特异性的 P-CAB（钾竞争性酸阻滞剂），用于治疗胃食管反流病。

Pantoprazole Sodium Hydrate (BY1023 (sodium hydrate)) 是一种具有口服活性的质子泵抑制剂。它是取代的苯并咪唑，是H+/K+-ATPase 抑制剂。它可改善 pH 值稳定性，具有抗分泌和抗溃疡的作用。它联合阿霉素可显著增加肿瘤生长延迟。

Vonoprazan Fumarate (TAK438) 是质子泵的有效抑制剂，是口服有效的高效钾竞争性酸阻断剂，具有抗分泌活性。在 pH 为 6.5 时，它抑制猪胃微粒体中的 H+,K+-ATPase 酶活性，IC50为 19 nM。它被开发用于研究酸相关疾病，如消化性溃疡和胃食管反流病。

Metoclopramide (5-Chloro-2-methoxyprocainamide) 是5-HT3和多巴胺D2受体拮抗剂，IC50值分别为 308 和 483 nM，可用于恶心呕吐、胃食管反流和胃轻瘫的研究。

Pantoprazole (BY1023) 是一种质子泵抑制剂，用于短期治疗由胃食管反流病引起的食管糜烂和溃疡。它联合阿霉素可显著增加肿瘤生长延迟。它是一种取代的苯并咪唑，是H+/K+-ATPase 抑制剂，可改善 pH 值稳定性，具有抗分泌和抗溃疡的作用。

Esomeprazole Magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) 是一种口服有效的H+, K+-ATPase 抑制剂，在上消化道疾病和胃食管反流疾病的研究中具有价值。它是一种外泌体抑制剂，通过抑制 V-H+-ATPases 来阻断外泌体的释放。

Lavoltidine (Loxtidine,拉伏替丁)是一种高效和选择性的H2受体拮抗剂，具有口服活性和不可逆性，能够抑制胃酸分泌并用于治疗胃食管反流病。

Lafutidine (FRG-8813) 是一种组胺受体 H2RA 拮抗剂，可抑制胃酸分泌，具有胃粘膜保护作用，可用于研究胃食管反流疾病。

Itopride HCl is an AChE inhibitor and dopamine D2 receptor antagonist. It inhibits lower esophageal sphincter relaxation. It also used to treat functional dyspepsia and gastroesophageal reflux disease

Pumosetrag Hydrochloride is an orally available 5-HT3 partial agonist. It is developed for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.

Revexepride is a highly selective agonist of the 5-HT4 receptor and a potential inducer of CYP3A4 enzyme. Revexepride is used for the treatment of gastroesophageal reflux disease.

Ilaprazole (IY-81149) 是一种具有口服活性质子泵抑制剂，以剂量依赖性方式不可逆地抑制H+/K+-ATPase，在兔壁细胞制剂中的IC50为 6 μM。它也是一种有效的T 细胞起源蛋白激酶(TOPK)抑制剂，用于胃溃疡的研究。

Ranitidine-S-oxide is a metabolite of Ranitidine. It is commonly used in the treatment of peptic ulcer disease, Zollinger–Ellison syndrome，and gastroesophageal reflux disease.

Lansoprazole sodium (Lansoprazole (sodium)) 是一种质子泵抑制剂，是中性鞘磷脂酶的外泌体抑制剂，能抑制胃酸生成。

Azeloprazole, a proton pump inhibitor, is used potentially for the treatment of gastroesophageal reflux disease (GERD).

Arbaclofen placarbil( XP19986) is a GABA(B) receptor agonist.Arbaclofen Placarbil is a novel R-baclofen prodrug with improved absorption, distribution, metabolism, and elimination properties compared to R-baclofen. And it can reduce postprandial reflux in

Famotine Hydrochloride is a histamine H2 receptor antagonist that suppresses acid production in the stomach and commonly treats peptic ulcer disease and gastroesophageal reflux disease.

Mitemcinal fumarate is a erythromycin derivative that is used to treat gastroesophageal reflux disease.

Esomeprazole magnesium salt is a potent and orally active proton pump inhibitor that effectively reduces acid secretion in gastric parietal cells by inhibiting the H+, K+-ATPase. This compound has shown promise for the research and treatment of symptomatic gastroesophageal reflux disease [1][2][3].

Vonoprazan hydrochloride 是一种高效且具口服活性的质子泵抑制剂 (PPI) 和钾竞争性酸阻断剂 (potassium-competitive acid blocker, P-CAB)，展示出优秀的抗分泌活性。在 pH 为 6.5 的条件下，该化合物可抑制猪胃微粒体内 H+,K+-ATPase 的酶活性，呈现出 19 nM 的 IC50 值。Vonoprazan hydrochloride 主要应用于胃酸相关疾病的研究，包括胃食管反流病和消化性溃疡，并可用于根除幽门螺杆菌。

Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is an effective and orally active proton pump inhibitor that works by inhibiting the H+, K+-ATPase enzyme in the gastric parietal cells, leading to a reduction in acid secretion. It is a promising compound for investigating symptomatic gastroesophageal reflux disease [1] [2] [3].

Esomeprazole hemistrontium, also known as (S)-Omeprazole, is a potent and orally active proton pump inhibitor that effectively reduces acid secretion by inhibiting the H+, K+-ATPase in gastric parietal cells. This compound exhibits promising potential for research in symptomatic gastroesophageal reflux disease [1] [2] [3].